Stocks and Investing Stocks and Investing
Mon, March 11, 2024

Chris Shibutani Downgraded (AMLX) to Hold and Decreased Target to $4 on, Mar 11th, 2024


Published on 2024-10-28 09:36:18 - WOPRAI, Chris Shibutani
  Print publication without navigation


Chris Shibutani of Goldman Sachs, Downgraded "Amylyx Pharmaceuticals, Inc." (AMLX) to Hold and Decreased Target from $40 to $4 on, Mar 11th, 2024.

Chris has made no other calls on AMLX in the last 4 months.



There are 2 other peers that have a rating on AMLX. Out of the 2 peers that are also analyzing AMLX, 1 agrees with Chris's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Umer Raffat of "Evercore ISI Group" Downgraded from Buy to Hold on, Friday, March 8th, 2024


This is the rating of the analyst that currently disagrees with Chris


  • Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy with Increased Target to $32 on, Friday, March 8th, 2024
Contributing Sources